← All news
Markets
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
Covered by 1 outlet
All coverage · 1 article